Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

126 results about "Lipid A" patented technology

Lipid A is a lipid component of an endotoxin held responsible for the toxicity of gram-negative bacteria. It is the innermost of the three regions of the lipopolysaccharide (LPS), also called endotoxin molecule, and its hydrophobic nature allows it to anchor the LPS to the outer membrane. While its toxic effects can be damaging, the sensing of lipid A by the human immune system may also be critical for the onset of immune responses to gram-negative infection, and for the subsequent successful fight against the infection.

Microneedle array vaccine adjuvant transmission system built by using lipid modifying carrier

The invention discloses a microneedle array which contains lipid modifying carrier and is used for a vaccine adjuvant transmission system. The microneedle array comprises a substrate and a plurality of microneedles fixed on the substrate, wherein the substrate is composed of saccharides, povidone, cellulose, or starch auxiliary materials; each microneedle comprises lipid A modifying carrier, the auxiliary materials (excipients) and vaccine ingredients; the lipid A modifying carrier can be lipidosome, lipid, micro-capsule or nanoparticle, and the like; the vaccine ingredients mainly refer to causative agent antigen proteins. Compared with the existing vaccine preparations, the lipid A-modified lipidosome microneedle array vaccine adjuvant transmission system can contain different vaccine ingredients to form vaccines aiming to different pathogens and therefore has a wide application scope. Biodegradable materials are selected and therefore the safety is high. The microneedle array vaccine adjuvant transmission system is a solid preparation which is high in stability and convenient to inoculate. Inoculation can be completed by a user self through oral mucosa, the vaccine can be prevented from running away along with saliva, and a body can be induced to establish mucosal immunity.
Owner:ANHUI MEDICAL UNIV

Factor c for treating gram-negative bacterial infection

Recombinant fragments of Factor C are disclosed. These proteins and peptides show great potency in recognizing, binding to, neutralizing and removing endotoxin. These molecules can thus be used for anti-microbial, anti-endotoxin, and anti-sepsis therapy. SSCrFCES is a 38 kDa protein representing the LPS-binding domain of Factor C. The ability of SSCrFCES to bind lipid A was analyzed using an ELISA-based assay as well as surface plasmon resonance. Surface plasmon resonance similarly carried out for SSCrFC-sushi-1,2,3-GFP, SSCrFC-sushi-1GFP, and SSCrFC-sushi-3GFP confirmed their superior affinity for endotoxin. The 50% endotoxin-neutralizing concentration of SSCrFCES against 200 EU of endotoxin is 0.069 μM, suggesting that SSCrFCES is an effective inhibitor of LAL coagulation cascade. Although partially attenuated by human serum, as low as 1 μM of SSCrFCES inhibits the LPS-induced secretion of hTNF-α and hIL-8 by THP-1 and human pheripheral blood mononuclear cells with a potency more superior than polymyxin B. SSCrFCES is non-cytotoxic, with a clearance rate of 4.7 ml / minute. The LD90 of SSCrFCES for LPS lethality in mice is achieved at 2 μM. These results demonstrate the endotoxin-neutralizing capability of SSCrFCES in vitro and in vivo, as well as its potential for use in the treatment of endotoxin-induced septic shock. Also embodied in this application is the use of the sushi peptides and their mutant derivatives as potent antimicrobials.
Owner:NAT UNIV OF SINGAPORE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products